Fig. 4From: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitorsAnterior segment photographs of two patients on FGFR inhibitors. Anterior segment photograph of case 10 patient. a The cornea of case 10 showed diffuse opacification, leaving the central part intact (yellow arrows Δ) at 190 days after the start of ASP-5878. b Unlike patients with EGFR inhibitor chemotherapy, this patient’s cornea showed epithelial staining along the demarcation of keratopathy (red arrows↑). c At 93 days after the discontinuation of the drug, both corneas were much improved and only thin opacification remained. d Under fluorescein staining, the epithelial staining appeared almost gone, leaving small peripheral lesions. Anterior segment photograph of case 11 patient. e At 446 days after the first intravenous injection of FPA-144, both corneas showed similar keratopathy findings, with superior and inferior demarcations (yellow arrows Δ). f Under fluorescein staining, there was corneal epithelial staining noted beyond the demarcation line (red arrows↑). g AT 218 days after the discontinuation of the drug, both corneas were considerably cleared. h Under fluorescein staining, the peripheral part of the left cornea showed epithelial staining that was much improved when compared with in (f)Back to article page